Literature DB >> 25724353

Ontogenic expression of human carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum: postnatal surge and organ-dependent regulation.

Yi-Tzai Chen1, Lynnie Trzoss1, Dongfang Yang1, Bingfang Yan2.   

Abstract

Human carboxylesterase-2 (CES2) and cytochrome P450 3A4 (CYP3A4) are two major drug metabolizing enzymes that play critical roles in hydrolytic and oxidative biotransformation, respectively. They share substrates but may have opposite effect on therapeutic potential such as the metabolism of the anticancer prodrug irinotecan. Both CES2 and CYP3A4 are expressed in the liver and the gastrointestinal tract. This study was conducted to determine whether CES2 and CYP3A4 are expressed under developmental regulation and whether the regulation occurs differentially between the liver and duodenum. A large number of tissues (112) were collected with majority of them from donors at 1-198 days of age. In addition, multi-sampling (liver, duodenum and jejunum) was performed in some donors. The expression was determined at mRNA and protein levels. In the liver, CES2 and CYP3A4 mRNA exhibited a postnatal surge (1 versus 2 months of age) by 2.7 and 29 fold, respectively. CYP3A4 but not CES2 mRNA in certain pediatric groups reached or even exceeded the adult level. The duodenal samples, on the other hand, showed a gene-specific expression pattern at mRNA level. CES2 mRNA increased with age but the opposite was true with CYP3A4 mRNA. The levels of CES2 and CYP3A4 protein, on the other hand, increased with age in both liver and duodenum. The multi-sampling study demonstrated significant correlation of CES2 expression between the duodenum and jejunum. However, neither duodenal nor jejunal expression correlated with hepatic expression of CES2. These findings establish that developmental regulation occurs in a gene and organ-dependent manner.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Carboxylesterases; Cytochrome P450; Drug metabolism; Ontogeny; Toxicology

Mesh:

Substances:

Year:  2015        PMID: 25724353      PMCID: PMC4496585          DOI: 10.1016/j.tox.2015.02.007

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  44 in total

1.  The intestine as an important contributor to prasugrel active metabolite formation in vivo.

Authors:  Katsunobu Hagihara; Miho Kazui; Hidenori Ikenaga; Toshihiko Nanba; Kiichi Fusegawa; Takashi Izumi; Toshihiko Ikeda; Atsushi Kurihara
Journal:  Drug Metab Dispos       Date:  2010-12-28       Impact factor: 3.922

2.  Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.

Authors:  R E Pearce; R R Gotschall; G L Kearns; J S Leeder
Journal:  Drug Metab Dispos       Date:  2001-12       Impact factor: 3.922

3.  Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats.

Authors:  W Zhu; L Song; H Zhang; L Matoney; E LeCluyse; B Yan
Journal:  Drug Metab Dispos       Date:  2000-02       Impact factor: 3.922

4.  Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression.

Authors:  Mingxing Xie; Dongfang Yang; Lan Liu; Bob Xue; Bingfang Yan
Journal:  Drug Metab Dispos       Date:  2002-05       Impact factor: 3.922

Review 5.  Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.

Authors:  R N Hines
Journal:  Int J Pharm       Date:  2012-07-03       Impact factor: 5.875

6.  Rat kidney carboxylesterase. Cloning, sequencing, cellular localization, and relationship to rat liver hydrolase.

Authors:  B Yan; D Yang; M Brady; A Parkinson
Journal:  J Biol Chem       Date:  1994-11-25       Impact factor: 5.157

7.  The human intestinal cytochrome P450 "pie".

Authors:  Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin
Journal:  Drug Metab Dispos       Date:  2006-02-07       Impact factor: 3.922

8.  Simultaneous substitution of phenylalanine-305 and aspartate-318 of rat pregnane X receptor with the corresponding human residues abolishes the ability to transactivate the CYP3A23 promoter.

Authors:  Xiulong Song; Yuxin Li; Jirong Liu; Madhu Mukundan; Bingfang Yan
Journal:  J Pharmacol Exp Ther       Date:  2004-09-14       Impact factor: 4.030

9.  RNA-sequencing quantification of hepatic ontogeny of phase-I enzymes in mice.

Authors:  Lai Peng; Julia Y Cui; Byunggil Yoo; Sumedha S Gunewardena; Hong Lu; Curtis D Klaassen; Xiao-Bo Zhong
Journal:  Drug Metab Dispos       Date:  2013-09-30       Impact factor: 3.922

10.  Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4.

Authors:  Shingo Takagi; Miki Nakajima; Takuya Mohri; Tsuyoshi Yokoi
Journal:  J Biol Chem       Date:  2008-02-11       Impact factor: 5.157

View more
  10 in total

1.  A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.

Authors:  Daniel Moj; Hannah Britz; Jürgen Burhenne; Clinton F Stewart; Gerlinde Egerer; Walter E Haefeli; Thorsten Lehr
Journal:  Cancer Chemother Pharmacol       Date:  2017-10-07       Impact factor: 3.333

2.  Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.

Authors:  Mikael Boberg; Marc Vrana; Aanchal Mehrotra; Robin E Pearce; Andrea Gaedigk; Deepak Kumar Bhatt; J Steven Leeder; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2016-11-28       Impact factor: 3.922

3.  Population pharmacokinetics of sildenafil in extremely premature infants.

Authors:  Daniel Gonzalez; Matthew M Laughon; P Brian Smith; Shufan Ge; Namasivayam Ambalavanan; Andrew Atz; Gregory M Sokol; Chi D Hornik; Dan Stewart; Gratias Mundakel; Brenda B Poindexter; Roger Gaedigk; Mary Mills; Michael Cohen-Wolkowiez; Karen Martz; Christoph P Hornik
Journal:  Br J Clin Pharmacol       Date:  2019-12-15       Impact factor: 3.716

Review 4.  Effects of pyrethroids on brain development and behavior: Deltamethrin.

Authors:  Emily M Pitzer; Michael T Williams; Charles V Vorhees
Journal:  Neurotoxicol Teratol       Date:  2021-04-20       Impact factor: 4.071

Review 5.  Recent advances in the ontogeny of drug disposition.

Authors:  Brian D Chapron; Alenka Chapron; J Steven Leeder
Journal:  Br J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.716

Review 6.  An update on the role of intestinal cytochrome P450 enzymes in drug disposition.

Authors:  Fang Xie; Xinxin Ding; Qing-Yu Zhang
Journal:  Acta Pharm Sin B       Date:  2016-08-04       Impact factor: 11.413

Review 7.  Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.

Authors:  Jean-Marie Nicolas; François Bouzom; Chanteux Hugues; Anna-Lena Ungell
Journal:  Biopharm Drug Dispos       Date:  2017-02-06       Impact factor: 1.627

Review 8.  Potential Applications of Chitosan-Based Nanomaterials to Surpass the Gastrointestinal Physiological Obstacles and Enhance the Intestinal Drug Absorption.

Authors:  Nutthapoom Pathomthongtaweechai; Chatchai Muanprasat
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

Review 9.  Ontogeny of Drug-Metabolizing Enzymes.

Authors:  Aarzoo Thakur; Md Masud Parvez; J Steven Leeder; Bhagwat Prasad
Journal:  Methods Mol Biol       Date:  2021

Review 10.  The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease.

Authors:  Matteo Tardelli; Francesca Virginia Bruschi; Michael Trauner
Journal:  Hepatology       Date:  2020-09       Impact factor: 17.425

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.